Special Mycology Laboratory-LEMI, Division of Infectious Diseases, Federal University of São Paulo, São Paulo, SP, Brazil; Division of Infectious Diseases, Hospital do Rim, São Paulo, SP, Brazil.
Division of Infectious Diseases, Federal University of São Paulo, São Paulo, SP, Brazil.
Clin Microbiol Infect. 2017 May;23(5):333.e9-333.e14. doi: 10.1016/j.cmi.2016.12.024. Epub 2017 Jan 3.
This is a retrospective and observational study addressing clinical and therapeutic aspects of melanized fungal infections in kidney transplant recipients.
We retrospectively reviewed medical records of all patients admitted between January 1996 and December 2013 in a single institution who developed infections by melanized fungi.
We reported on 56 patients aged between 30 and 74 years with phaeohyphomycosis or chromoblastomycosis (0.54 cases per 100 kidney transplants). The median time to diagnosis post-transplant was 31.2 months. Thirty-four (60.8%) infections were reported in deceased donor recipients. Fifty-one cases of phaeohyphomycosis were restricted to subcutaneous tissues, followed by two cases with pneumonia and one with brain involvement. Most dermatological lesions were represented by cysts (23/51; 45.1%) or nodules (9/51; 17.9%). Exophiala spp. (34.2%) followed by Alternaria spp. (7.9%) were the most frequent pathogens. Graft loss and death occurred in two patients and one patient, respectively. Regarding episodes of subcutaneous phaeohyphomycosis, a complete surgical excision without antifungal therapy was possible in 21 of 51 (41.2%) patients. Long periods of itraconazole were required to treat the other 30 (58.8%) episodes of subcutaneous disease. All four cases of chromoblastomycosis were treated only with antifungal therapy.
Melanized fungal infections should be considered in the differential diagnosis of all chronic skin lesions in transplant recipients. It is suggested that the impact of these infections on graft function and mortality is low. The reduction in immunosuppression should be limited to severely ill patients.
本回顾性观察性研究旨在探讨肾移植受者中黑真菌感染的临床和治疗方面。
我们回顾性分析了 1996 年 1 月至 2013 年 12 月期间在一家机构住院的所有发生黑真菌感染的患者的病历。
我们报告了 56 例年龄在 30 至 74 岁之间的患者,患有暗色丝孢霉病或着色芽生菌病(每 100 例肾移植中有 0.54 例)。移植后诊断的中位数时间为 31.2 个月。34 例(60.8%)感染发生在已故供体受者中。51 例暗色丝孢霉病仅局限于皮下组织,随后有 2 例肺炎和 1 例脑部受累。大多数皮肤病变表现为囊肿(23/51;45.1%)或结节(9/51;17.9%)。外瓶霉属(34.2%)和链格孢属(7.9%)是最常见的病原体。移植物丢失和死亡分别发生在 2 例和 1 例患者中。对于 51 例皮下暗色丝孢霉病患者,21 例(41.2%)患者在不进行抗真菌治疗的情况下完全手术切除。对于其余 30 例(58.8%)皮下疾病患者,需要长期使用伊曲康唑治疗。所有 4 例着色芽生菌病仅用抗真菌治疗。
在移植受者的所有慢性皮肤病变的鉴别诊断中,应考虑黑真菌感染。建议这些感染对移植物功能和死亡率的影响较低。应将免疫抑制的减少仅限于重病患者。